Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results‐Medicare analysis

Background Cisplatin and cetuximab are both systemic therapies commonly used in combination with radiation (RT) for the definitive treatment of head and neck cancers, but their comparative efficacy is unclear. Methods Patients with locoregionally advanced (American Joint Committee on Cancer stage II...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2018-12, Vol.124 (23), p.4486-4494
Hauptverfasser:	Xiang, Michael, Holsinger, F. Christopher, Colevas, A. Dimitrios, Chen, Michelle M., Le, Quynh‐Thu, Beadle, Beth M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Cancer therapies Carcinoma, Squamous Cell - therapy cetuximab Cetuximab - adverse effects Cetuximab - therapeutic use chemoradiotherapy Chemoradiotherapy - adverse effects Chemoradiotherapy - methods Cisplatin Cisplatin - adverse effects Cisplatin - therapeutic use Clinical Trials as Topic Confidence intervals Dermatitis Dysphagia Epidemiology Female Filtration Government programs Head & neck cancer head and neck neoplasms Head and Neck Neoplasms - therapy Health care Health risks Humans Hypopharyngeal Neoplasms - therapy Hypopharynx Immunotherapy Laryngeal carcinoma Laryngeal Neoplasms - therapy Larynx Male Medicare Monoclonal antibodies Mucositis Neoplasm Staging Oncology Oropharyngeal Neoplasms - therapy Oropharyngolaryngeal carcinoma Oropharynx Patients propensity score Radiation Radiation therapy Regression analysis SEER Program Squamous cell carcinoma Statistical analysis Surveillance Survival Survival Analysis Targeted cancer therapy Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!